2.1. Subjects
peptic ulcer disease, infection, renal deficiency
PEPTIC ULCER DISEASE, INFECTION, ALLERGY TO LOCAL ANESTHETIC, INFLAMMATORY BOWEL DISEASE
This study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2018-160-02) and registered in the Chinese Clinical Trial Registry (ChiCTR2100054057, A total of 132 patients with lung nodules receiving VATS with general anesthesia (the GA Group), ultrasound-guided RIB (RIB Group), or PVB (the PVB Group) in the plane of the T5 level using 0.4% ropivacaine (Zhejiang Xianju Pharmaceutical Co., Ltd., Zhejiang, China) at 3 mg/kg between June 8th, 2022, and August 10th, 2022, were recruited.Inclusion criteria are as follows: (1) 18–80 years of age; (2) American Society of Anesthesiologists (ASA) Class I-III; and (3) written informed consent was obtained.Exclusion criteria are as follows: (1) Allergy to local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids; (2) infection of the skin at the puncture site; (3) peptic ulcer disease or inflammatory bowel disease; (4) renal deficiency; (5) transferring to thoracotomy; (6) daily use of opioids; and (7) bilateral operation.